Introduction {#Sec1}
============

Instillation of therapeutic agents into the bladder to combat recurrent urinary tract infections (rUTIs) has been part of clinical practice since the 1960s \[[@CR1], [@CR2], [@CR3]•, [@CR4]--[@CR7], [@CR8]•, [@CR9]--[@CR11]\]. These are usually reserved as end of line strategy. The inexorable rise in antimicrobial resistance (AMR) has demanded an urgent need for novel solutions for treatment of rUTIs.

Inappropriate use of broad-spectrum antibiotic treatments is considered to have largely contributed to this era of high resistance patterns \[[@CR12]\]. Infections associated with such virulent pathogens have become increasingly difficult to manage and often require higher doses or alternative medications. With a paucity of new antibiotics on the horizon, changing the route or regimen of current antibiotic use has become the subject of increased attention. A potential way forward has been the use of intravesical antibiotics (IVA), which have been shown to have greater effect on bacteria at a local level while reducing systemic absorption and its associated side effects \[[@CR13]--[@CR16]\].

The aim of our systematic review was to collate available evidence on the effectiveness of IVA in the prevention and treatment of recurrent urinary infections and to give an overview of the available literature to date.

Material and Methods {#Sec2}
====================

Evidence acquisition: criteria for including studies for this review

Inclusion criteria:All English language articles (reporting ≥ 3 patients) of all age groups including paediatric studiesStudies reporting on IVA for prevention and treatments of rUTIs

Exclusion criteria:Case reports, review articles, animal and laboratory studiesStudies reporting on non-antibiotic intravesical instillations

Search Strategy and Study Selection {#Sec3}
===================================

The systematic review was performed according to the Cochrane and preferred reporting items for systematic reviews and meta-analyses (PRISMA) standards \[[@CR17]\]. The search strategy was conducted to find all relevant abstracts and publications about bladder antimicrobial instillations for rUTI.

The databases searched included MEDLINE, Scopus, Biomed Central, EMBASE, CINAHL and Web of Science with references cross-checked and individual urology journals hand-searched. The search strategy was conducted to find all relevant abstracts regarding 'recurrent urinary tract infection', 'UTI', 'intravesical', 'antimicrobial bladder irrigation', 'intravesical antimicrobial therapy', 'bladder irrigation', 'antibiotic intravesical treatment', 'instillation', 'treatment', 'prophylaxis', 'recurrent cystitis' and 'methods of bladder irrigations'. Boolean operators (AND, OR) were employed to augment the search. The research was limited to English language articles from inception to August 2017. The list of studies generated by the search was screened to identify eligible studies.

Data Extraction and Outcomes of Interest {#Sec4}
----------------------------------------

The data extraction was carried out by two authors (AP and BS) and any discrepancy was resolved by mutual consensus. Authors were contacted directly in cases of missing data or uncertainty. Primary outcomes of interest were successful treatment or prevention of rUTIs. Data was also collected on method of IVA delivery, follow-up, any change in AMR sensitivity, discontinuation from treatment and the IVA schedule and dose used. While success was defined as reduction in culture positive or symptomatic UTIs, some studies also looked at the change in antibiotic sensitivity with the use of IVA. Due a lack of trials, only pooled analysis of mean results and narrative descriptions have been carried out.

Results {#Sec5}
=======

After an initial identification of 658 studies, 37 abstracts were screened followed by review of 18 full text articles (Fig. [1](#Fig1){ref-type="fig"}). Eleven of these were included in our final review. This included 285 patients, of which 168 (6 studies, 59%) had IVA as a treatment of rUTI and 117 (5 studies, 41%) had IVA as prophylaxis for rUTI. Except one trial with only 30 participants, all other studies were observational studies \[[@CR6]\].Fig. 1PRISMA flowchart of the included studies

Baseline Population Characteristics (Table [1](#Tab1){ref-type="table"}) {#Sec6}
------------------------------------------------------------------------

The mean age participants in the included studies were 52 years with a male to female ratio of 1:1 (Table [1](#Tab1){ref-type="table"}). Although majority of studies (7/11) used gentamicin as the IVA, this included 3 where it was used as treatment and 4 where it was used a prophylaxis against rUTI \[[@CR2], [@CR4], [@CR5], [@CR8]••, [@CR9], [@CR10]•, [@CR11]\]. The other IVA used were a combination of neomycin/polymyxin (*n* = 2) and isolated neomycin and colistin in one study each \[[@CR1], [@CR3]•, [@CR6], [@CR7]\]. The majority of participants had neurogenic bladders, indwelling catheters or performed intermittent self-catheterisation (ISC), although studies also had patients with urinary diversion (Table [2](#Tab2){ref-type="table"}). All participants had rUTIs when oral antibiotic therapy had failed.Table 1Characteristics of the selected studiesJournalAuthorsIntravesical antibioticPublication dateType of study*N* of patientsMean ageUnderlining pathologyMale:femaleAuthor's definition of recurrent UTITreatment for recurrent UTI 1*The Journal of Spinal Cord medicine*Todd et al.Neomycin/polymyxin2016Retrospective12NASCI with indwelling catheter7:3Failed response to oral antibiotic (2 courses) 2*The Journal of Urology*Defoor et al.Gentamicin2006Retrospective8010Neuropathic bladder, bladder exstrophy, cloacal anomalies, Hinman syndrome, vesicoureteral reflux, hypospadias, posterior urethral valves, bladder reconstruction, renal transplantation38:42Failed response to oral antibiotic (2 courses) 3*Infection*Giua et al.Colistin2013Retrospective375SCI, mechanical ventilation2:1Failed response to oral antibiotic (2 courses) 4*Infect Urol*Arap et al.Gentamicin2003Retrospective1870Recurrent UTI0:18Failed response to oral antibiotic (2 courses) 5*The Journal of Urology*McGuire et al.Gentamicin1987Case series467Bladder dysfunction, high residual0:4Failed response to oral antibiotic (2 courses)Prophylaxis for recurrent UTI 6*The Journal of Spinal Cord medicine*Waites et al.Neomycin/polymyxin2006Randomised30NASCI, neurogenic bladder with indwelling catheter or SPCNARecurrent microscopic bacteriuria and pyuria 7*Antimicrobial Agents and Chemotherapy*Haldorson et al.Neomycin1978Prospective53NASCI, vascular disease, MS, cancer33:20Recurrent bacteriuria during intermittent catheterisation 8*Neurourology and Urodynamics*Abrams et al.Gentamicin2017Retrospective2755Neobladders, neurophatic bladder, ileocystoplasty, ISC7:20Recurrent UTI, failed oral prophylaxis 9*Translational Andrology and Urology*Dray VE et al.Gentamicin2017Retrospective22NAPatients who required ISCNA4 UTIs in the preceding 6-month period 10*Canadian Urological Association Journal*Cox et al.Gentamicin2017Prospective2237.5SCI, MS, myelodysplasia transverse myelitis22:154 UTIs in the preceding 6-month period 11*Meeting of the Infectious Diseases Society of America*Stalenhoef et al.Gentamicin2013Retrospective1460ISC, chronic bacterial prostatitis, vesicoureteral reflux and neobladder8:6Recurrent UTI despite, failed oral prophylaxis*NA* not available, *SCI* spinal cord injury, *ISC* intermittent self-catheterisation, *MS* multiple sclerosisTable 2Characteristics of the intravesical therapyIntravesical antibioticAdministrationSerum levelSuccessful outcome\*Follow-up (range)Change in sensitivity\*\*Unchanged resistanceDiscontinuationReasonsTreatment for recurrent UTI 1Neomycin/polymyxinStaffNot checked9/12 (75%)6 months (no range)9/12 (75%)3/12 (25%)2/12 (16%)Allergy 2GentamicinParentsYes negligible75/80 (93.7%)90 days (3--1095)16/80(20%)5/80 (6%)Variable not trackable0 3ColistinStaffNot checked3/3 (100%)NA2/3 (66%)0/31/3 (33%)1 suprapubic discomfort 4GentamicinISCYes negligible12/18 (66%)65.1 months (15--103)03/18 (16%)3/18 (16%)UTI 5GentamicinISCNot checked4/4 (100%)22 weeks (18--24)0000Overall treatment outcomes103/117 (88%)27/117 (23%)11/117 (9%)6/117 (5%)Prophylaxis for recurrent UTI 6Neomycin/polymyxinSelfNot checked23/30 (76%)8 weeks (no range)19/30 (63%)7/30 (23%)8/30 (26%)4 UTIs, 4 other health-related issues 7NeomycinStaffNot checked16/53 (30%)6 weeks (1--19)NA37/53 (70%)0NA 8GentamicinSelfYes negligible27/27 (100%)24 months (2--67)18/27 (66%)1/27 (3%)6/27 (22%)Infection, stones, cystectomy, nephrectomy, bladder stone 9GentamicinSelf/carerYes negligible22/22 (100%)NANA0NANA 10GentamicinSelfNot checked22/22 (100%)6 weeks (no range)9/22 (40%)8/22 (36%)00 11GentamicinSelfYes negligible10/14 (71%)42 weeks (6--148)4/14 (28%)2/14 (14%)00Overall treatment outcomes120/168 (71%)50/168 (30%)55/168 (32%)14/168 (8%)*NA* not available\*Successful outcome is met in those where the irrigation procedure had to eradicate all of the organisms or change the sensitivities so oral antibiotics could be given\*\*Resistant organism was eradicated, or the sensitivity changed to one that could be treated with an oral antibiotic

Outcomes {#Sec7}
--------

The majority of the participants who underwent the antimicrobial instillation showed a good response with a reduction of symptomatic UTI in 78.2% (*n* = 223) (Table [2](#Tab2){ref-type="table"}). A high success rate of 88% (*n* = 103%) was seen in the treatment group in the short term (3--6 months) \[[@CR1], [@CR2], [@CR3]•, [@CR4], [@CR5]\], with a low discontinuation rate of 5% (*n* = 6). A success rate of 71% (*n* = 120) was seen in the prophylaxis group in the short term \[[@CR6], [@CR7], [@CR8]••, [@CR9], [@CR10]•, [@CR11]\], with a discontinuation rate of 8% (*n* = 14).

Effect of IVA {#Sec8}
-------------

Overall, there was a change in the sensitivity of organisms in 30% (*n* = 50) and 23% (*n* = 27) in the treatment and prophylaxis groups respectively, which meant that either the resistant organism was eradicated or the sensitivity changed so that further treatment could be carried out with oral antibiotics.

Overall, 20 patients discontinued their IVA instillation (6 in the treatment group, 14 in the prophylaxis group). The gentamicin group had a discontinuation rate of 5% (*n* = 9), which was 3% (*n* = 3) for treatment group and 7% (*n* = 6) for the prophylaxis group. The non-gentamicin group had a discontinuation rate of 11% (*n* = 11), which was 20% (*n* = 3) for the treatment group and 10% (*n* = 8) for the prophylaxis group.

While the side effects of treatment were not well documented in studies, most reported were minor and included allergy, suprapubic discomfort, autonomic dysreflexia, urinary tract infections and diarrhoea (Table [3](#Tab3){ref-type="table"}). A slight increase in serum levels of gentamicin was also seen in 4% (*n* = 3) in one series (2).Table 3Dose, duration and side effects of antibiotics used for intravesical treatmentDrugDoseDurationSide effectTreatment for recurrent UTI  1Neomycin/polymyxin30 ml3/day for 5 daysAllergy  2Gentamicin0.48 mg/ml in 30 ml normal saline2/dayMinor rise in serum creatinine for 3 patients with chronic renal insufficiency 3Colistin3.5 mg 0.42% dissolved in 500 ml of saline solution3/day for 7 days1 suprapubic discomfort 4Gentamicin480 mg + 1 l saline solution+100 ml sodium carbonate30 ml daily for 1 week, then alternate days for 6 weeks (2 months)3 UTI 5Gentamicin20 ml of 240 mg in 1 l saline solution4 ISC/day0Prophylaxis for recurrent UTI 6Neomycin/polymyxin30 of 40 mg/ml neomycin sulfate and 200,000 units/ml polymyxin B2/day for 8 weeks2 autonomic dysreflexia 7Neomycin0.1% of neomycin solutionAfter each intermittent catheterisationnd 8Gentamicin80 mg in 10 ml saline solutionNightly0 9Gentamicin14.4--28.8 mg in 30--60 ml of saline solutionNightly0 10Gentamicin14.4--28.8 mg in 30--60 ml of saline solutionNightly1 yeast infection, 1 diarrhoea 11Gentamicin80 mg in 20 ml of saline solutionDaily then once a week0*UTI* urinary tract infection, *ISC* intermittent self-catheterisation, *nd* no data

Discussion {#Sec9}
==========

Meaning of the Study {#Sec10}
--------------------

This is the first review of its kind on the role of IVA for prophylaxis and treatment of rUTIs. The overall short-term success rate seems to be good, in regard to both its role in prophylaxis and treatment. It is associated with low risk of complications and discontinuation rates of between 5 and 8%.

Role of IVA {#Sec11}
-----------

The earlier reports on IVA date back to 1967 when most studies were case reports. It was in 1996 that Hajjar et al. described a strain of resistant bacteria due to indiscriminate antibiotic use and reported a case of vancomycin bladder irrigation (via a three-way catheter) to treat MRSA \[[@CR18]\]. Then, in 1978, Haldorson et al. tested the use of neomycin in reducing bacteriuria in a case-control group after ISC \[[@CR7]\]. In 2004, Wood et al. described a successful case of tobramycin bladder irrigation for UTI in a critically ill patient \[[@CR14]\]. Since then, other studies about intravesical agents have been described with wider cohorts of patients.

Other non-antimicrobial intravesical instillations such as hyaluronic acid and chondroitin sulfate have also been used \[[@CR15]\]. During our literature research, we also identified other antimicrobials such as tobramicin, linezolid and vancomycin which have been used as IVA. However, these results were mostly limited to isolated case reports \[[@CR12], [@CR14], [@CR18]\].

The majority of patients with rUTIs, either from idiopathic UTI or due to an underlining pathology, often have a poor quality of life. In the presence of underlying risk factors such as spinal cord injury (SCI), urinary diversion or intermittent self-catheterisation (ISC) \[[@CR2], [@CR3]•, [@CR4]--[@CR7], [@CR8]••, [@CR9], [@CR10]•, [@CR11]\], it is marked by frequent hospital admissions with repeated use of wide-spectrum intravenous antibiotics \[[@CR13]\]. However, over time, there is development of both bacterial resistance and the systemic side effects that are well recognised after protracted courses of intravenous and oral antibiotics \[[@CR15]\]. Waites and colleagues also demonstrated that oral antibiotics change the urinary, perineal and urethral flora of neurogenic bladder patients \[[@CR6]\].

While gentamicin was the most common IVA used, the dosage varied in different studies \[[@CR8]••, [@CR12]\]. Wan et al. studied the safety and efficacy of intravesical gentamicin instillations in rat models \[[@CR19]\]. They demonstrated that although severe bladder inflammation and anatomical abnormalities can increase transvesical absorption of gentamicin, serum gentamicin levels were still in the therapeutic range. Canine models showed that despite the presence of vesicoureteric reflux (VUR), serum gentamicin levels were not detectable after intravesical instillation \[[@CR19], [@CR20]\]. Furthermore, they also studied 10 children who were performing ISC for neurogenic bladder dysfunction, and none had detectable levels of serum gentamicin at 30-min post-instillation, with no adverse reactions noted \[[@CR19]\]. A similar test was carried out by Defoor et al. in 80 paediatric patients and none of them were found to have a serum gentamicin level greater than 0.4 μg/ml \[[@CR2]\]. Small increases in serum creatinine were seen in 3 patients with chronic renal insufficiency. However, this was believed to be attributable to the progression of the native renal disease.

IVA not only seems to decrease the frequency of symptomatic infections, but potentially seems to play a role in reducing the need for oral antibiotics. While gentamicin seems to be more widely used and has shown to be effective in the bladder, other IVA have not had a similar response and currently seem to have insufficient clinical evidence due to a lack of adequate published data on them \[[@CR8]••\].

Limitations and Areas of Future Research {#Sec12}
----------------------------------------

Our review is limited by the observational and retrospective nature of most studies and limited data for management of end of line rUTIs. Only one small randomised trial was identified \[[@CR6]\]. Although the majority of studies used gentamicin, not all did so and both dosage and schedules were not standardised. The gentamicin dose used varied from 14.4 to 480 mg mixed in saline with no fixed treatment duration recommended for it. This is likely due to the rarity of this treatment and uncertainty amongst clinicians and microbiologists as to the most appropriate regimen. The systematic side effects of IVA perhaps have not fully been explored \[[@CR21]\], but intermittent, single-dose regimens are unlikely to have systemic side effects. The role of intravesical non-antibiotic treatments for rUTIs also needs to be better defined as there is some data to support this \[[@CR22]\].

Although the standardisation of IVA treatment will be a topic of future research, patient compliance and long-term follow-up will be required to establish the true benefit in patients with rUTIs. Despite methodological limitations, given the rarity of this treatment, the potential benefit of IVA for prophylaxis and treatment of patients with rUTIs cannot be ignored. It is therefore important to have protocol-based collaborative centre studies supported by a large sample size to establish the role of IVA in these patients. Ideally, this needs to be addressed by an RCT with a placebo or non-antibiotic comparator, evaluating not only the treatment outcomes but also on the drug dosages, instillation regime, quality of life and cost associated with it.

Conclusions {#Sec13}
===========

Intravesical antimicrobial instillation seems to be a relatively safe and effective method for the prophylaxis and treatment of recurrent UTIs, especially in the short term. It gives clinicians an alternative treatment modality in high-risk patients predisposed to UTIs where all other forms of systemic treatments have failed.
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